Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000668241 | SCV000792814 | likely pathogenic | Bardet-Biedl syndrome 12 | 2017-07-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001388449 | SCV001589447 | pathogenic | Bardet-Biedl syndrome | 2020-06-25 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the BBS12 protein. Other variant(s) that disrupt this region (p.Arg675*) have been determined to be pathogenic (PMID: 20827784, 21642631). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant has not been reported in the literature in individuals with BBS12-related conditions. ClinVar contains an entry for this variant (Variation ID: 552893). This variant is not present in population databases (ExAC no frequency). This sequence change results in a premature translational stop signal in the BBS12 gene (p.Ser650*). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 61 amino acids of the BBS12 protein. |